NHI.no
Annonse
Informasjon

Amyotrofisk lateralsklerose (ALS)

Amyotrofisk lateralsklerose (ALS) er en sykdom som i tiltagende omfang ødelegger de motoriske nervecellene i ryggmarg, hjernestamme og motoriske del av hjernebarken.

Symptomer på ALS starter ofte med at man føler seg klossete med hendene.

Sist oppdatert:

21. des. 2021

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Amyotrofisk lateralsklerose . Referanselisten for dette dokumentet vises nedenfor

  1. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1603471 DOI
  2. Ola Nakken: “Epidemiology of Amyotrophic Lateral Sclerosis: A population-based study in Norway”. Doktorgradsavhandling, Ahus. 12. februar 2020. www.med.uio.no
  3. Ince PG and Codd GA. Return of the cycad hypothesis: does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? Neuropathol Appl Neurobiol 2005; 31: 345-53. PubMed
  4. McDermott CJ. Amyotrophic lateral sclerosis. BestPractice, last updated March 2020.
  5. Chiò A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, Giannini F, Mandrioli J, Mora G, Sabatelli M; the ITALSGEN Consortium,, Ajmone C, Mastro E, Pain D, Mandich P, Penco S, Restagno G, Zollino M, Surbone A. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014. pmid: 23833266 PubMed
  6. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No.: CD001447. DOI: 10.1002/14651858.CD001447.pub3. DOI
  7. Orrell RW, Lane RJM, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002829. DOI: 10.1002/14651858.CD002829.pub4. DOI
  8. Colman E, Szarfman A, Wyeth J et al. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA’s spontaneous adverse event reporting system. United States Food and Drug 2008; : DOI: 10.1002/pds.1643. DOI
  9. Gadoth A, Nefussy B, Bleiberg M, et al. Transglutaminase 6 antibodies in the serum of patients with amyotrophic lateral sclerosis. JAMA Neurol 2015; 72: 676-81. pmid:25867286 PubMed
  10. Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ.. The cognitive profile of ALS: a systematic review and meta-analysis update.. J Neurol Neurosurg Psychiatry 2015. pmid:26283685 PubMed
  11. Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral sclerosis. Lancet Neurol 2015; 14: 435-42. pmid:25728958 PubMed
  12. Chipika RH, Mulkerrin G, Murad A, et al. Alterations in somatosensory, visual and auditory pathways in amyotrophic lateral sclerosis: an under-recognised facet of ALS. J Integr Neurosci 2022; 21: 88. pmid:35633169 PubMed
  13. Batty GD, Gale CR. Pre-Morbid Risk Factors for Amyotrophic Lateral Sclerosis: Prospective Cohort Study. Clin Epidemiol. 2021 Oct 7;13:941-947. . PMID: 34675682. PubMed
  14. Mattsson P, Lönnstedt I, Nygren I, Askmark H. Physical fitness, but not muscle strength, is a risk factor for death in amyotrophic lateral sclerosis at an early age. J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):390-4. PubMed
  15. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. Neurology 2012; 79: 1970-1974. pmid:22955124 PubMed
  16. World Federation of Neurology Research Group on Motor Neuron Diseases, El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis http://www.wfnals.org/guidelines/1998elescorial/elescorial1998.htm (accessed Feb 18, 2007).
  17. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat PF, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis .Eur J Neurol. 2012 Mar;19(3):360-75. doi: 10.1111/j.1468-1331.2011.03501.x. DOI
  18. Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):303-309. Epub 2019 Mar 20. PMID: 30892087. PubMed
  19. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66: 647-53. Neurology
  20. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD004429. DOI: 10.1002/14651858.CD004429.pub2. DOI
  21. Umapathi T, Hughes RAC, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No.: CD003217. DOI: 10.1002/14651858.CD003217.pub5. The Cochrane Library
  22. Chiò A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 2014;13(12):1228-1240. doi:10.1016/S1474-4422(14)70167-X DOI
  23. Van Laere K1, Vanhee A2, Verschueren J3, De Coster L3, Driesen A2, Dupont P2, Robberecht W4, Van Damme P4. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014; May;71(5): 553-61. pmid:24615479 PubMed
  24. Cosgrove J, Jamieson S, Chowdhury FU. Teaching NeuroImages: Hypometabolism of the primary motor cortex in primary lateral sclerosis: The stripe sign. Neurology 2015;84(24):e206. doi:26078407
  25. Leirvik A, Liverød M, Holmøy T. Livskvalitet hos pasienter med amyotrofisk lateral sklerose. Tidsskr Nor Lægeforen 2006; 126: 2520-2. PubMed
  26. Holmøy T, Worren T. Kommunikasjonshjelpemidler ved amyotrofisk lateral sklerose. Tidsskr Nor Lægeforen 2006; 126: 2523-5. PubMed
  27. Beauverd M, Mitchell JD, Wokke JHJ, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD002064. The Cochrane Library
  28. Holmøy T, Ljøstad U, Mygland Å. Amyotrofisk lateral sklerose. Nevro-NEL, sist oppdatert 12.10.2020. nevrologi.legehandboka.no
  29. Banfi P, Ticozzi N, Lax A, Guidugli GA, Nicolini A, Silani V. A Review of Options for Treating Sialorrhea in Amyotrophic Lateral Sclerosis. Respir Care 2014. pmid:25228780 PubMed
  30. Kubler A, Nijboer F, Mellinger J, et al. Patients with ALS can use sensorimotor rhythms to operate a brain-computer interface. Neurology 2005; 64: 1775-7. Neurology
  31. Morrow B, Zampoli M, van Aswegen H, Argent A. Mechanical insufflation-exsufflation for people with neuromuscular disorders. Cochrane Database of Syst Rev. 2013, Issue 12. Art. No.: CD010044. DOI: 10.1002/14651858.CD010044.pub2. DOI
  32. Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology 2005; 65: 62-7. Neurology
  33. Lewis CM, Suzuki M. Therapeutic applications of mesenchymal stem cells for amyotrophic lateral sclerosis. Stem Cell Res Ther 2014; 5: 32. pmid:25157751 PubMed
  34. Neudert C, Oliver D, Wasner M and Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248: 612-6. PubMed
  35. Calvo A, Canosa A, Bertuzzo D, et al. Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1229-1233 . pmid:
  36. Shefner JM, Al-Chalabi AA, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020; 131: 1975-1978. pmid:32387049 PubMed
  37. Turner MR, UK MND Clinical Studies Group. Diagnosing ALS: the Gold Coast criteria and the role of EMG. Pract Neurol 2022; 22: 176-178. pmid:34992096 PubMed
Annonse
Annonse